Asymmetric Total Synthesis of (-)-Swainsonine from Inexpensive and Commercially Available Starting Material, Ascorbic Acid
Zheng Yang Lee1, Mohd Fazli Mohammat2, Agustono Wibowo3, and Jhi Biau Foo1,4*
Journal of Angiotherapy 6(3) 714-715 https://doi.org/10.25163/angiotherapy.6320C
Submitted: 24 December 2022 Revised: 24 December 2022 Published: 24 December 2022
Abstract
Introduction: Swainsonine is a natural and synthetic alpha-mannosidase II inhibitor which has been shown to inhibit various types of cancer growth in vitro and in vivo. Our initial study was to synthesise (-)-swainsonine from commercially available D-isoascorbic acid, yet unsuccessful, although following published protocol. Hence, we envisioned this challenge associated with aldehyde-lactol tautomerism by exploiting another novel route. Methods: Acetonide protected diol 1 was first prepared from D-isoascorbic acid via a three-step procedure. It was then selectively acetylated, and further Swern oxidation yielded aldehyde 2. Wittig olefination was carried out to afford olefinic ester 3 with ease. Subsequent deacetylation and azide substitution gave imino ester 6, which readily produces (-)-swainsonine in 4 steps. Purification of the products was carried out using the classical column chromatography Si-gel G60 (230-400 mesh, Merck). The 1H and 13C NMR spectra were registered in CDCl3 with Joel Resonance ECZ400S 400 MHz (1H) and 100 MHz (13C) using TMS as the internal standard. Results: The imino ester 6 was obtained as a colourless oil with an overall yield of 2% from D-isoascorbic acid. Conclusion: The present study illustrated the total synthesis route of (-)-swainsonine.
Keywords: Swainsonine, Cancer, Swern oxidation, Wittig olefination, Aldehyde-lactol tautomerism
References
View Dimensions
View Altmetric
Save
Citation
View
Share